SCHEMBL5841363

SCHEMBL5841363

O=C1Cc2cc(S(=O)(=O)NC3CCC3)ccc2N1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 3/20 0.79
PKM P14618 2/20 0.54
IDO1 P14902 1/20 0.54
GAA P10253 2/20 0.53
KDM4E B2RXH2 1/20 0.51
RECQL P46063 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TDP1 Q9NUW8 3/20 0.51
MAPT P10636 1/20 0.51
ALDH1A1 P00352 1/20 0.49
GLO1 Q04760 1/20 0.48
EPHX2 P34913 1/20 0.48
MGAT2 Q10469 1/20 0.47
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842119 0.97 SMYD3 (0.79) SMYD3PKMIDO1GAAKDM4E
SCHEMBL5841238 0.96 SMYD3 (0.77) SMYD3PKMIDO1GAAKDM4E
SCHEMBL5843084 0.94 SMYD3 (0.88) SMYD3PKMIDO1GAAKDM4E
SCHEMBL21489896 0.88 SMYD3 (1.00) SMYD3PKMIDO1GAATDP1
SCHEMBL19710713 0.88 SMYD3 (1.00) SMYD3PKMIDO1GAATDP1
SCHEMBL12431390 0.87 SMYD3 (0.72) SMYD3PKMIDO1GAATDP1
SCHEMBL12431391 0.84 SMYD3 (0.67) SMYD3PKMIDO1GAATDP1
SCHEMBL516838 0.82 SMYD3 (0.69) SMYD3PKMIDO1GAATDP1
SCHEMBL516839 0.82 SMYD3 (0.69) SMYD3PKMIDO1GAATDP1
SCHEMBL19710353 0.81 SMYD3 (0.69) SMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 US claimed
EP-1294688-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2003-03-26 EP claimed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 US claimed
WO-2001094312-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-12-13 WO claimed
US-7071332-B2 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. (US) 2006-07-04 US disclosed
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 US disclosed
US-6706709-B2 TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER SUGEN, INC. 2004-03-16 US disclosed
EP-1294688-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2003-03-26 EP disclosed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 US disclosed
WO-2001094312-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 SMYD3 2338/4885PKM 246/4885IDO1 584/4885
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 SMYD3 2338/4885PKM 246/4885IDO1 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.